Compare OGN & WEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OGN | WEN |
|---|---|---|
| Founded | 1923 | 1969 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Restaurants |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 2020 | 2000 |
| Metric | OGN | WEN |
|---|---|---|
| Price | $13.75 | $9.12 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 22 |
| Target Price | ★ $11.40 | $8.84 |
| AVG Volume (30 Days) | 2.6M | ★ 9.5M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | 0.60% | ★ 8.28% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.95 | 0.29 |
| Revenue | ★ $6,216,000,000.00 | $2,176,891,000.00 |
| Revenue This Year | $0.45 | $2.26 |
| Revenue Next Year | $1.67 | $0.94 |
| P/E Ratio | ★ $14.47 | $30.48 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $5.69 | $6.07 |
| 52 Week High | $13.76 | $10.62 |
| Indicator | OGN | WEN |
|---|---|---|
| Relative Strength Index (RSI) | 72.40 | 61.52 |
| Support Level | $13.46 | $7.84 |
| Resistance Level | N/A | $9.45 |
| Average True Range (ATR) | 0.04 | 0.39 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 93.18 | 90.91 |
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
The Wendy's Co is engaged in operating, developing, and franchising a system of distinctive quick-service restaurants serving high-quality food. The company operates through Wendy's U.S., Wendy's International, and Global Real Estate & Development. Wendy's U.S. and Wendy's International include the operation and franchising of restaurants and derive revenues from sales at company-operated restaurants, as well as royalties, franchise fees, and advertising fund collections from franchised restaurants. Global Real Estate & Development includes real estate activities for owned and leased sites that are leased or subleased to franchisees and includes the company's share of income from its Canadian restaurant real estate joint venture.